Marshall Wace LLP Invests $175,000 in uniQure (NASDAQ:QURE)

Marshall Wace LLP purchased a new position in shares of uniQure (NASDAQ:QURE) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 39,078 shares of the biotechnology company’s stock, valued at approximately $175,000.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares during the period. Acadian Asset Management LLC grew its holdings in uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 350,291 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in uniQure by 74.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock valued at $818,000 after purchasing an additional 66,958 shares during the period. BNP Paribas Financial Markets grew its holdings in uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after purchasing an additional 30,054 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in uniQure during the second quarter valued at approximately $815,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Up 4.2 %

uniQure stock opened at $5.65 on Friday. The stock has a market capitalization of $274.30 million, a PE ratio of -0.91 and a beta of 0.95. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average of $5.89 and a 200-day moving average of $5.63.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.08. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $3.47 million. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. On average, equities research analysts anticipate that uniQure will post -4.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday, August 20th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Monday, August 5th. Raymond James reiterated an “outperform” rating and issued a $20.00 price target on shares of uniQure in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price target on shares of uniQure in a report on Friday, September 20th. Finally, The Goldman Sachs Group upped their price target on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.50.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.